Victoria Simms
The NEW clinically validated NGS and bioinformatics solution for hereditary cancer testing: GALEAS Hereditary Plus – All you need to know
By Victoria Simms on February 28, 2024 | Reviewed by Celina Whalley Cancer is the leading cause of death worldwide, affecting millions of people each year.1 There are over 200 different types, each with their own unique characteristics and treatment approaches.2 While their causes are complex and multifaceted, one subset gaining increased attention is hereditary cancer; constituting 5-10%…
Read MoreHereditary cancer testing: Challenges and opportunities for genomic centres
Hereditary cancer testing has become a valuable tool in healthcare, contributing to the understanding and identification of individuals’ susceptibility to cancer.
Read MoreHow our custom NGS panels are being used for clinical utility
Targeted Next Generation Sequencing (NGS) panels have revolutionized clinical diagnosis and treatment of genetic disorders and cancers by being able to precisely identify disease-associated variants.
Read MoreThe power of SPRI technology: Tips for DNA size selection and effective clean-up in NGS workflows
Since its introduction into genomics in 1995, Solid Phase Reversible Immobilization (SPRI) technology, in the form of magnetic beads, has become mainstream in laboratory protocols for nucleic acid extraction and purification.
Read MoreThe NEW sample-to-report NGS bladder cancer test: GALEAS Bladder – All you need to know
To improve bladder cancer management for both patients and clinicians, Nonacus developed and launched GALEAS Bladder.
Read MoreTo consolidate multiple testing strategies for hematological malignancies, our customer designed the first Nonacus NGS panel for both myeloid and lymphoid neoplasia
To help consolidate multiple testing strategies for haematological malignancies, our customer designed a Nonacus NGS panel, creating the first NGS workflow for both myeloid and lymphoid neoplasia.
Read MoreDetecting copy number variants using Next Generation Sequencing
By Victoria Simms on June 29, 2023 Copy number variants can have big consequences on our health – so detecting them reliably and robustly is important – is NGS up to the job? Copy number variants (CNVs) are responsible for 5-10% of genetic disease – that’s why detecting them reliably and robustly is so important…
Read MoreCan you use NGS panels to test for tumor mutational burden?
Written by Victoria Simms, April 24, 2023. Reviewed by Celina Whalley, April 22, 2024 Tumor mutational burden (TMB) has been highlighted as a reliable predictor of immunotherapy response across multiple cancer types, offering the potential to help guide immunotherapy treatment decisions for cancer patients. Typically whole genome sequencing (WGS) and whole exome sequencing (WES) are…
Read More5 Tips for using the Nonacus Panel Design Tool
By Victoria Simms on December 20, 2022. Reviewed by Celina Whalley, April 26, 2024 Get great coverage for the genes you care about Do you need to create a custom NGS panel? Read our tips to find out how to create and optimise your panel design At Nonacus, we have developed an intuitive, online Panel…
Read More